[EN] L-DOPA AND/OR DOPA DECARBOXYLSE INHIBITORS CONJUGATED TO SUGAR FOR THE TREATMENT OF DOPAMINE-RESPONSIVE DISORDERS<br/>[FR] INHIBITEURS DE L-DOPA ET/OU DOPA-DÉCARBOXYLASE CONJUGUÉS AU SUCRE POUR LE TRAITEMENT DE TROUBLES SENSIBLES À LA DOPAMINE
申请人:B G NEGEV TECHNOLOGIES AND APPLICATIONS LTD AT BEN GURION UNIV
公开号:WO2020115753A1
公开(公告)日:2020-06-11
The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L- DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and/or DOPA decarboxylse inhibitor/ s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.
本发明提供了共轭物,包括糖,例如甘露醇和一个或多个L-DOPA和/或DOPA脱羧酶抑制剂,包括但不限于L-DOPA,卡比多巴,苯丝肼或其组合物,其中糖通过糖的羟基与L-DOPA和/或DOPA脱羧酶抑制剂的羧基结合。本发明还提供相关的制药组合物和制备共轭物的方法,以及用于治疗对多巴胺能刺激有反应的医疗疾病的使用方法,例如运动障碍,包括但不限于帕金森病。